Magnesium supplements with cisplatin chemotherapy

European Journal of Cancer

Volumn 32, Issue 3, 1996, Pages 556-557

  Lofts, F J ^a   Evans, T R J ^a   Wastnage, R ^a   Mansi, J L ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; MAGNESIUM;

CANCER; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; HUMAN; HYPOMAGNESEMIA; LETTER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG COSTS; HUMANS; MAGNESIUM; MAGNESIUM SULFATE;

EID: 0013511940     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00599-4     Document Type: Letter

References (2)

1. Evans TRJ, Harper CL, Beveridge IG, Wastnage R, Mansi JL. A randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracil. Eur J Cancer 1995, 31A, 174-178.
2. Safirstein R, Winston J, Goldstein M, et al. Cisplatin nephrotoxicity. Am J Kidney Dis 1986, 5, 356-367.